Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer's Disease
- PMID: 33684513
- DOI: 10.1016/j.pneurobio.2021.102031
Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer's Disease
Abstract
What happens precociously to the brain destined to develop Alzheimer's Disease (AD) still remains to be elucidated and this is one reason why effective AD treatments are missing. Recent experimental and clinical studies indicate that the degeneration of the dopaminergic (DA) neurons in the Ventral Tegmental Area (VTA) could be one of the first events occurring in AD. However, the causes of the increased vulnerability of DA neurons in AD are missing. Here, we deeply investigate the physiology of DA neurons in the VTA before, at the onset, and after onset of VTA neurodegeneration. We use the Tg2576 mouse model of AD, overexpressing a mutated form of the human APP, to identify molecular _targets that can be manipulated pharmacologically. We show that in Tg2576 mice, DA neurons of the VTA at the onset of degeneration undergo slight but functionally relevant changes in their electrophysiological properties and cell morphology. Importantly, these changes are associated with accumulation of autophagosomes, suggestive of a dysfunctional autophagy, and with enhanced activation of c-Abl, a tyrosine kinase previously implicated in the pathogenesis of neurodegenerative diseases. Chronic treatment of Tg2576 mice with Nilotinib, a validated c-Abl inhibitor, reduces c-Abl phosphorylation, improves autophagy, reduces Aβ levels and - more importantly - prevents degeneration as well as functional and morphological alterations in DA neurons of the VTA. Interestingly, the drug prevents the reduction of DA outflow to the hippocampus and ameliorates hippocampal-related cognitive functions. Our results strive to identify early pathological brain changes in AD, to provide a rational basis for new therapeutic interventions able to slow down the disease progression.
Keywords: Autophagy; Midbrain; Tg2576; Tyrosine kinase; Ventral Tegmental Area.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Comment in
-
_targeting autophagy as a therapeutic strategy to prevent dopamine neuron loss in early stages of Alzheimer disease.Autophagy. 2021 May;17(5):1278-1280. doi: 10.1080/15548627.2021.1909409. Epub 2021 Apr 5. Autophagy. 2021. PMID: 33779492 Free PMC article.
Similar articles
-
_targeting autophagy as a therapeutic strategy to prevent dopamine neuron loss in early stages of Alzheimer disease.Autophagy. 2021 May;17(5):1278-1280. doi: 10.1080/15548627.2021.1909409. Epub 2021 Apr 5. Autophagy. 2021. PMID: 33779492 Free PMC article.
-
Upregulation of Ca2+-binding proteins contributes to VTA dopamine neuron survival in the early phases of Alzheimer's disease in Tg2576 mice.Mol Neurodegener. 2022 Nov 25;17(1):76. doi: 10.1186/s13024-022-00580-6. Mol Neurodegener. 2022. PMID: 36434727 Free PMC article.
-
Early derailment of firing properties in CA1 pyramidal cells of the ventral hippocampus in an Alzheimer's disease mouse model.Exp Neurol. 2022 Apr;350:113969. doi: 10.1016/j.expneurol.2021.113969. Epub 2021 Dec 31. Exp Neurol. 2022. PMID: 34973962
-
Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care.Neurosci Biobehav Rev. 2013 Sep;37(8):1363-79. doi: 10.1016/j.neubiorev.2013.05.008. Epub 2013 May 24. Neurosci Biobehav Rev. 2013. PMID: 23707776 Review.
-
The Raphe Dopamine System: Roles in Salience Encoding, Memory Expression, and Addiction.Trends Neurosci. 2021 May;44(5):366-377. doi: 10.1016/j.tins.2021.01.002. Epub 2021 Feb 8. Trends Neurosci. 2021. PMID: 33568331 Review.
Cited by
-
Dopamine neuron degeneration in the Ventral Tegmental Area causes hippocampal hyperexcitability in experimental Alzheimer's Disease.Mol Psychiatry. 2024 May;29(5):1265-1280. doi: 10.1038/s41380-024-02408-9. Epub 2024 Jan 16. Mol Psychiatry. 2024. PMID: 38228889 Free PMC article.
-
The Role of c-Abl Tyrosine Kinase in Brain and Its Pathologies.Cells. 2023 Aug 10;12(16):2041. doi: 10.3390/cells12162041. Cells. 2023. PMID: 37626851 Free PMC article. Review.
-
Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer's disease.J Neuroinflammation. 2023 May 16;20(1):116. doi: 10.1186/s12974-023-02802-0. J Neuroinflammation. 2023. PMID: 37194065 Free PMC article.
-
Nilotinib as a Prospective Treatment for Alzheimer's Disease: Effect on Proteins Involved in Neurodegeneration and Neuronal Homeostasis.Life (Basel). 2024 Sep 28;14(10):1241. doi: 10.3390/life14101241. Life (Basel). 2024. PMID: 39459541 Free PMC article.
-
Abl depletion via autophagy mediates the beneficial effects of quercetin against Alzheimer pathology across species.Cell Death Discov. 2023 Oct 14;9(1):376. doi: 10.1038/s41420-023-01592-x. Cell Death Discov. 2023. PMID: 37838776 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous